Medical Health Blog

AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system, which measures central blood pressure and arterial stiffness noninvasively, announced the publication of a new NIH-funded study*, published in the Journal of Hypertension, found that central (aortic) blood pressure, measured noninvasively with AtCor’s SphygmoCor system, is a more important indicator of the development of left ventricular hypertrophy (LVH) than is brachial blood pressure. LVH relates to muscle thickening in the heart’s pumping chamber…

A just published research experiment on inactive men with high blood pressure shows that just 3 months of soccer practise twice a week causes a significant fall in blood pressure, resting pulse rate, and percentage of body fat, and is more effective than the doctor’s usual advice on healthy diet and exercise…

Gilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo…

A first Phase II trial with Bayer Schering Pharma’s oral agent riociguat (BAY 63-2521) in pulmonary hypertension owing to interstitial lung disease (PH-ILD) has successfully been completed. PH-ILD is a form of pulmonary hypertension for which no approved treatment options are currently available. The primary objectives of the study to investigate safety and tolerability of riociguat in this subgroup of PH-patients were achieved…

Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound (“HTI-101″), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension. The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a novel low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and statistically met its primary endpoint…

Does stress increase blood pressure? This simple question has been the focus of intense research for many years. Now new research has for the first time established a link between a novel gene, phosducin, and the blood pressure response to stress in mice as well as humans…

Patients whose hypertension is managed by a physician-pharmacist team have lower blood pressure levels and are more likely to reach goals for blood pressure control than those treated without this collaborative approach, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Do stressful situations make your blood pressure rise? If so, your phosducin gene could be to blame according to a team of researchers, at the University of Freiburg, Germany, and the Medical College of Wisconsin, Milwaukee, that has identified a role for the protein generated by the phosducin gene in modulating blood pressure in response to stress in both mice and humans.

New studies show Transcendental Meditation™ reduces blood pressure in students and almost halves heart attacks – UK case studies available The first randomised controlled trial to demonstrate that a mental technique can reduce blood pressure in at-risk university students – through impr

Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.